News & Events

A clinical trial based on Molab predictions starts at Ciudad Real hospital
Ciudad Real General Hospital
Wednesday September 12, 2018

A clinical trial based on Molab predictions starts at Ciudad Real hospital

In 2015 a paper by Molab researchers together with the group of cellular biology of the School of Medicine of the University of Castilla-La Mancha [1] predicted the potential benefitial role of antioxidants in combination with cytotoxic therapies for the treatment of glioblastoma.

With the help of a grant of the James S. Mc. Donnell Foundation (USA) some of the phenomena predicted were found to happen in different glioblastoma models [2,3].

Now, a clinical trial directed by the researchers of the group of cellular biology has started recruiting patients with the collaboration of the involved medical services: Neurosurgery, Radiology, Radiation Oncology, Medical Oncology, Nuclear Medicine and Pathology. Molab researchers will also take part through the analysis of the imaging data (MRI and PET) to understand quantitatively the effect of the combinations in real patients. 


[1] A. Martínez-González, M. Durán-Pardo, G. F. Calvo, F. J. Alcaín, L. A. Pérez-Romasanta, V.M. Pérez-García. Combined therapies of antithrombotics and antioxidants delay in silico brain tumors progression. Mathematical Medicine and Biology 32, 239-262 (2015)

[2] J Frontiñán, R Santiago, C Nieva, G Ferrín, A Martínez, MV Gomez, M Moreno, J Ariza, E Lozano, J Arjona, A Gil, M De la Mata, M Pesic, JR Peinado, JM Villalba, L Pérez-Romasanta, et al. Regulation of the oxidative balance with Coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide. Radiotherapy and Oncology (2018).

[3] Stojkovic S, Podolski-Renic A, Dinic J, Stankovic T, Jovanovic M, Hadžic S, Ayuso JM, Virumbrales-Muñoz M, Fernández LJ, Ochoa I, Perez-Garcia VM, Pešic M, Modulation of antioxidant potential with coenzyme Q10 suppressed invasion of temozolomide resistant rat glioma in vitro and in vivo. Oxidative Medicine and Cellular Regeneration (submitted, 2018)

Last News and events